NEW YORK (GenomeWeb) – Epigenomics reported today that its second quarter revenues dropped 81 percent due to lower orders of its Epi proColon colorectal cancer test and a continued lack of reimbursement coverage for its products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.